Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of IV GTX-104 vs Oral Nimodipine in Healthy Subjects
NCT05418348Phase 1Completed
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GTX-104 in aneurysmal subarachnoid hemorrhage (SAH) (2 arms), sponsored by Grace Therapeutics, Inc. Primary endpoints: Maximum Plasma Concentration (Cmax) Day 1 and Area Under the Curve (AUC) Day 3. Started Aug 2021; status: completed.
02
Drugs
GTX-104
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT05418348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418348.